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ABSTRACT During 2010 and 2012, California and Vermont, respectively, experi-
enced statewide epidemics of pertussis with differences seen in the demographic af-
fected, case clinical presentation, and molecular epidemiology of the circulating
strains. To overcome limitations of the current molecular typing methods for pertus-
sis, we utilized whole-genome sequencing to gain a broader understanding of how
current circulating strains are causing large epidemics. Through the use of combined
next-generation sequencing technologies, this study compared de novo, single-
contig genome assemblies from 31 out of 33 Bordetella pertussis isolates collected
during two separate pertussis statewide epidemics and 2 resequenced vaccine
strains. Final genome architecture assemblies were verified with whole-genome opti-
cal mapping. Sixteen distinct genome rearrangement profiles were observed in epi-
demic isolate genomes, all of which were distinct from the genome structures of the
two resequenced vaccine strains. These rearrangements appear to be mediated by
repetitive sequence elements, such as high-copy-number mobile genetic elements
and rRNA operons. Additionally, novel and previously identified single nucleotide
polymorphisms were detected in 10 virulence-related genes in the epidemic isolates.
Whole-genome variation analysis identified state-specific variants, and coding re-
gions bearing nonsynonymous mutations were classified into functional annotated
orthologous groups. Comprehensive studies on whole genomes are needed to un-
derstand the resurgence of pertussis and develop novel tools to better characterize
the molecular epidemiology of evolving B. pertussis populations.
IMPORTANCE Pertussis, or whooping cough, is the most poorly controlled
vaccine-preventable bacterial disease in the United States, which has experienced a
resurgence for more than a decade. Once viewed as a monomorphic pathogen,
B. pertussis strains circulating during epidemics exhibit diversity visible on a genome
structural level, previously undetectable by traditional sequence analysis using short-
read technologies. For the first time, we combine short- and long-read sequencing
platforms with restriction optical mapping for single-contig, de novo assembly of 31
isolates to investigate two geographically and temporally independent U.S. pertussis
epidemics. These complete genomes reshape our understanding of B. pertussis evo-
lution and strengthen molecular epidemiology toward one day understanding the
resurgence of pertussis.
KEYWORDS: Bordetella pertussis, genome rearrangements, optical mapping,
pertactin, whole-genome sequencing
Received 9 February 2016 Accepted 3 April
2016 Published 11 May 2016
Citation Bowden KE, Weigand MR, Peng Y,
Cassiday PK, Sammons S, Knipe K, Rowe LA,
Loparev V, Sheth M, Weening K, Tondella ML,
Williams MM. 2016. Genome structural diversity
among 31 Bordetella pertussis isolates from two
recent U.S. whooping cough statewide
epidemics. mSphere 1(3):e00036-16. doi:
10.1128/mSphere.00036-16.
Editor Melanie Blokesch, Swiss Federal
Institute of Technology Lausanne
Copyright © 2016 Bowden et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Margaret M.
Williams, cux6@cdc.gov.
RESEARCH ARTICLE
Molecular Biology and Physiology
crossmark
Volume 1 Issue 3 e00036-16 msphere.asm.org 1
Bordetella pertussis is the causative agent of whooping cough (pertussis), a respira-tory disease affecting all age groups, but with the highest disease severity in
unvaccinated infants. Whole-cell vaccines against pertussis were introduced in the
United States during the 1940s, and greatly reduced disease incidence, but were
replaced during the 1990s by acellular vaccines, which produced less-severe side effects
(1–4). In addition to diphtheria and tetanus toxoids, the entire childhood vaccination
series of diphtheria–tetanus–acellular-pertussis (DTaP) vaccine contains inactivated
pertussis toxin (Ptx) and one or more additional virulence-related bacterial compo-
nents: filamentous hemagglutinin (Fha), pertactin (Prn), or fimbria (Fim) types 2 and 3.
Additionally, a single dose of the adolescent and adult booster Tdap (diphtheria,
tetanus, and acellular-pertussis vaccine) was recommended in 2005 to counteract the
rise of reported cases in adolescents and adults (3, 5, 6). Despite availability, adminis-
tration, and high coverage of the acellular vaccine reported in the country as a whole,
pertussis cases in the United States over the past decade have increased to record
numbers not seen since the 1950s. Many states have experienced epidemic levels of
pertussis cases in recent years, specifically California in 2010 and Washington and
Vermont in 2012 (7–11). In 2010, California reported over 9,000 cases (23.4 cases per
100,000 residents), while in 2012 Vermont reported over 600 cases (103 cases per
100,000 residents), over 10 times more than average for that time of year (7, 10). With
incidence being highest in unvaccinated infants younger than 6 months and fully
vaccinated preadolescents (7 to 10 years) in California, previous studies concluded that
unprotected infants were at the highest risk for disease, while waning protection from
the childhood acellular vaccine series contributed to disease in preadolescents (7, 12).
While there is no single explanation for this resurgence of cases, it has been ascribed
to many factors such as pathogen adaptation, improved surveillance and laboratory
diagnostics, and waning protection and immune response provided by the acellular
vaccine (12–14).
Since 2010, the U.S. population of circulating B. pertussis strains has increasingly
become deficient in Prn, an acellular vaccine component, due to various mutations,
primarily the disruption of prn by the mobile genetic element IS481 (11, 14–18). In 2012,
92% of isolates collected in Vermont did not produce pertactin, suggesting that a
selective advantage to prn deficiency may have played a role in that epidemic (14). In
separate global locations, two isolates lacking Ptx have been obtained recently, one of
which is also Prn deficient (19, 20). The loss of vaccine immunogens identified by
current molecular typing methods provides strong evidence that current populations
of B. pertussis no longer reflect the genotypic profile of vaccine strains and could be
adapting to the immune response elicited by the acellular vaccine (11, 14, 15, 19,
21–24). This, along with data supporting higher rates of evolution in vaccine antigen
genes, has generated concern that other genes encoding vaccine components may
harbor mutations not identifiable through current molecular typing techniques (25).
Additionally, the recent analysis of a statewide pertussis epidemic in Washington
during 2012 revealed that pulsed-field gel electrophoresis (PFGE), a whole-genome
restriction digest analysis, was the most powerful indicator of diversity in this popula-
tion of circulating pertussis strains (11). With evidence suggesting that current strains
exhibit genomic diversity that nucleotide variation identified by short-read sequencing
fails to explain, it is of great interest to employ long-read technologies to detect
mutations and assess the role of genome structure in pertussis resurgence (11, 15, 26).
With hundreds of insertion sequences (ISs) and repeat regions in current circulating
strains of B. pertussis, whole-genome sequencing is challenging. There are currently
over 400 B. pertussis draft genomes available in public databases, all of which include
at least 200 contigs assembled from short-read sequencing. Such fragmented assem-
blies provide limited information about genome arrangement or gene order and are,
therefore, not suitable for evaluating contributions of rearrangement diversity toward
pertussis incidence, resurgence, or strain evolution. Complete, de novo genome assem-
bly of B. pertussis is essential in pursuit of this information and now possible with
long-read (1-kb) sequencing and whole-genome mapping (27, 28). The recent release
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of complete genomes highlights the contrast between modern pertussis strains and
current vaccine references, at both the nucleotide and the structural levels (29, 30). In
an effort to better understand pertussis resurgence and evolution, here we characterize
genome structure and provide direct evidence of large genome rearrangements in
annotated, single-contig genome assemblies from 31 isolates collected during two
geographically and temporally distinct pertussis epidemics. This depth of resolution
facilitates analysis that is not possible through conventional molecular typing or
short-read sequencing. The availability of these complete genomes will hopefully aid
future transcriptomics and proteomics pursuits toward a deeper understanding of
pertussis reemergence and increased incidence.
RESULTS
Reference-free assembly of complete genomes. Through the use of Pacific Biosci-
ences (PacBio) RSII and Illumina MiSeq sequencing technologies, 33 genomes (31
epidemic, 2 vaccine) (Table 1) were de novo assembled into single contigs. All genomes
were approximately 4.1 Mb in size with an average GC content of 67.7%. Detailed
assembly metrics for each genome are outlined in Data Set S1 in the supplemental
material. The genome assembly of I475 provided no circular overlap to ensure closing
of the single contig, while the genome assemblies for I488 and I517 failed one or more
validation steps, resulting in multiple contig(s). Annotation information, including the
number of genes, coding sequences (CDS), pseudogenes, frameshifted genes, and
insertion sequences, is outlined in Data Set S1 in the supplemental material. In addition,
all genomes contained 51 tRNAs and 3 rRNA operons. Tohama I (E476) and the Chinese
vaccine (CS) strain (C393) resequenced in this study were 16.8 kb and 9.5 kb larger than
the NCBI reference genomes Tohama I and CS, respectively, due to the discovery of
additional IS481 copies (see Data Set S1).
Large-scale genome rearrangements. Multiple insertions, deletions, and inver-
sions were seen in all genomes of epidemic isolates relative to E476 and C393 using
both optical mapping and whole-genome sequence alignment (Fig. 1). Such genome
structural diversity was also observed within epidemic isolates, which included 16
discrete, large-scale architectural profiles. The 13 California genomes comprised 10
rearrangement profiles, and 11 profiles were seen in the 18 Vermont genomes. Further,
only five structural profiles were observed in both states, with five and six additional
profiles distinct to California and Vermont, respectively (examples of these structural
profiles can be found in Fig. S1B in the supplemental material).
To visualize the dynamic relationship between the vaccine strains and isolates
collected during the California and Vermont epidemics resulting from genome struc-
tural changes, a Maximum Likelihood for Gene Order (MLGO) tree was constructed from
a multiple sequence alignment (Fig. 2). This clustering revealed eight major clades (A
to H) that distinguished the epidemic isolates and vaccine strains based on gene
rearrangement and gene order (Fig. 2). Isolates with the same or similar PFGE profiles
clustered by genome rearrangement (Fig. 2). The vaccine strains formed a distinct clade
(H) which is distant from the U.S. epidemic isolates and B1917 (CP009751) and B1920
(CP009752) (29). B1917, the ptxP3 lineage strain corresponding to current circulating
strains, clusters with isolates in clade D, while B1920, the ptxP1 lineage strain predom-
inant from 1960 to the 1990s, is no more closely related to I646 and the only ptxP1
epidemic isolate (H375) than it is to the rest of the epidemic and vaccine strain
genomes (Fig. 2) (29). Four clades (B, D, E, and F) show clustering of epidemic isolates
by state and prn production status. Further, the two isolates collected in Vermont
during 2011 (H788 and I669) are diverse and not closely related to each other by
genome structure (Fig. 2).
Rearrangement boundaries. To better understand what mediates observed
rearrangements, the genome content at each predicted rearrangement boundary was
investigated further. When comparing California and Vermont isolates alone, 26 con-
served homologous blocks (1.5 kb) were identified in these 31 genomes, separated by
25 predicted rearrangement boundaries (Table 2; see also Fig. S1 in the supplemental
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material). Eighty percent (n  20) of these boundaries were composed of an IS481
element (Table 2; see also Fig. S1B). Additionally, 12% (n  3) were composed of an rrn
operon, while two boundaries were composed of either an IS1002 element or a
combination of IS1002 and IS481 (Table 2; see also Fig. S1B). When two vaccine strains
(C393 and E476) were included in the alignment, all additional predicted rearrange-
ment boundaries contained IS481 (Table 2). This larger comparison identified 45
conserved homologous blocks (1.5 kb), separated by 44 predicted rearrangement
boundaries, 89% (n  39) of which included copies of IS481 (Table 2).
Virulence gene comparisons. The sequences of 44 virulence-related genes for all
epidemic genomes and C393 were compared to E476 (see Data Set S2 in the supple-
mental material). The resulting alignments revealed that 30 of these virulence-related
TABLE 1 Metadata for B. pertussis isolates collected during the California 2010 and Vermont 2012 statewide epidemics and vaccine















H374 CA 2010 Infant UV CDC002 16 2 3 1 1 WT prn 
H375e CA 2010 Infant UV CDC268 186 1 1 2 1 Del nt 26-109f 
H378 CA 2010 Infant UV CDC253 27 2 3 1 1 IS481::240 Fwdg 
H379 CA 2010 Infant UV CDC046 27 2 3 1 2 WT prn 
H380e CA 2010 Infant UV CDC013 27 2 3 1 2 WT prn 
H489 CA 2010 Infant UV CDC082 27 2 3 1 2 WT prn 
H542e CA 2010 Infant UV CDC269 27 2 3 1 1 WT prn 
H559e CA 2010 Infant UV CDC253 27 2 3 1 1 IS481::240 Fwdg 
H561 CA 2010 Infant UV CDC170 16 2 3 1 2 WT prn 
H563e CA 2010 Infant 1 dose CDC271 27 2 3 1 2 WT prn 
H564 CA 2010 Child UV CDC013 27 2 3 1 2 WT prn 
H622 CA 2010 Infant UV CDC217 27 2 3 1 1 WT prn 
H627 CA 2010 Infant UV CDC217 27 2 3 1 1 WT prn 
H788 VT 2011 Infant UV CDC046 128 2 3 1 2 WT prn 
I669 VT 2011 Adult UV CDC013 27 2 3 1 2 WT prn 
I468 VT 2012 Child UV CDC002 27 2 3 1 1 SC @ nt 1273 
I469 VT 2012 Child 1 dose CDC342 27 2 3 1 2 IS481::1613 Revh 
I472 VT 2012 Adolescent UV CDC046 27 2 3 1 2 IS481::1613 Revh 
I475 VT 2012 Adult UV CDC237 27 2 3 1 1 IS481::1613 Fwdi 
I476 VT 2012 Adolescent UTD CDC300 27 2 3 1 1 IS481::1613 Fwdi 
I480 VT 2012 Child 1 dose CDC217 27 2 3 1 1 WT prn 
I483 VT 2012 Infant UTD CDC237 27 2 3 1 1 IS481::1613 Fwdi 
I488 VT 2012 Child 1 dose CDC343 27 2 3 1 1 IS481::1613 Fwdi 
I496 VT 2012 Child UTD CDC343 27 2 3 1 1 IS481::1613 Fwdi 
I498 VT 2012 Adult 1 dose CDC253 27 2 3 1 1 IS481::240 Revj 
I517 VT 2012 Child 1 dose CDC344 27 2 3 1 1 IS481::1613 Fwdi 
I518 VT 2012 Child UTD CDC002 27 2 3 1 1 SC @ nt 1273 
I521 VT 2012 Child 1 dose CDC237 27 2 3 1 1 IS481::1613 Fwdi 
I538 VT 2012 Child UNK CDC002 27 2 3 1 1 prnP (–74 nt)k 
I539 VT 2012 Child UTD CDC002 27 2 3 1 1 prnP (–74 nt)k 
I646 VT 2012 Child UV CDC274 27 2 3 1 1 WT prn 
I656 VT 2012 Child UTD CDC010 27 2 3 1 1 WT prn 
I707 VT 2012 Child UTD CDC253 27 2 3 1 1 WT prn 
C393 China 1951 UNK NA CDC052 UNK 1 1 2 1 WT prn 
E476 Japan 1954 UNK NA CDC232 38 1 1 2 1 WT prn 
aMLVA type is defined by the repeat counts for VNTR1, VNTR3, VNTR4, VNTR5, and VNTR6 (21).
bSingle-copy locus (21).
cFormerly referred to as fim3.
dBased on enzyme-linked immunosorbent assay.
eFatal cases.
fSignal sequence deletion (nt 26 to 109).
gIS481 forward insertion at nt 240.
hIS481 reverse insertion at nt 1613.
iIS481 forward insertion at nt 1613.
jIS481 reverse insertion at nt 240.
kPromoter disruption (–74 nt), previously identified as promoter inversion (11, 15).
lAbbreviations: MLVA, multilocus variable-number tandem-repeat analysis; CA, California; VT, Vermont; nt, nucleotide; UTD, up to date; UV, unvaccinated; UNK,
unknown; WT, wild-type; SC, stop codon; NA, not applicable.
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genes showed no sequence differences relative to E476. Gene sequences extracted
from the assemblies for prn, ptxP, ptxA, and fimH (fim3) exhibited the same allelic
variations previously identified through multilocus sequence typing (MLST) and prn
sequence typing by PCR (Table 1; see also Data Set S2). Unique single nucleotide
polymorphisms (SNPs) identified in virulence-related genes of the epidemic isolates are
displayed in Table 3 and in Data Set S2 in the supplemental material. Six SNPs in
virulence-related genes were found to be unique to a single isolate, while two were
identified in all epidemic isolates, including C393 (Table 3). Most of the SNPs identified
(7/10) resulted in an amino acid change (Table 3). Interestingly, a majority of SNPs in
B. pertussis  C393  [KpnI]
B. pertussis  H561  [KpnI]
B. pertussis  H563 [KpnI]
B. pertussis  I496  [KpnI]
B. pertussis  I707 [KpnI]








FIG 1 Large-scale genome rearrangements within a subset of California (H561 and H563, blue) and Vermont (I496 and I707, red) epidemic isolates
compared to vaccine strains E476 and C393 as visualized by whole-genome restriction mapping and alignment with MapSolver (A) and genome sequence
alignment with progressiveMauve (B). Connecting lines indicate either conserved restriction fragments (A) or homologous sequence blocks (B). Sequence
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FIG 2 Maximum likelihood for gene order (MLGO) clustering of epidemic strains from the 2010 California (blue) and 2012 Vermont (red)
statewide pertussis epidemics. Publicly available genomes (Tohama I, CS, B1917, and B1920) and two resequenced vaccine strains (C393 and
E476) were also included (black). Pertactin production and deficiency of each strain are indicated by pink and black boxes, respectively.
Clades referenced within the text are indicated by letters. The inset displays banding patterns of the PFGE profiles of all epidemic and
vaccine strains sequenced in this study. The dendrogram of PFGE profiles was created using the unweighted pair group method using
average linkages (UPGMA) with 1% band tolerance and optimization settings. Genomes for the epidemic isolates I488 and I517 were
excluded from the analysis (see Materials and Methods and Data Set S1 in the supplemental material).
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virulence-related genes were found in GC-rich regions (Table 3). Additionally, no
epidemic genomes harbored the 23S A2047G mutation known to produce erythromy-
cin/azithromycin resistance (31–33).
Variant analysis. The phylogenetic relationships among epidemic isolates were
reconstructed from a concatenated alignment of 408 variable sites (Fig. 3). There was
greater diversity among the 13 California isolates (Fig. 3), with H375 being most
divergent, and no clustering was observed among isolates recovered from fatal cases
(Fig. 3). In contrast, Vermont isolates exhibited more homogeneity (Fig. 3). Additionally,
four California genomes (H563, H561, H374, and H564) clustered among the earliest
collected Vermont genomes, three of which (H788, I475, and I669) were collected from
unvaccinated patients (Fig. 3). Pertactin-deficient and pertactin-producing isolates are
dispersed throughout the tree (Fig. 3). The two isolates with the prn promoter disrup-
tion (I538 and I539) are exclusive to one clade (Fig. 3; Table 1).
To characterize putative phenotypic effects of observed nucleotide variants, all
mutations were classified as noncoding, synonymous, or nonsynonymous, as seen in
Fig. 4. Within the 33 epidemic genomes analyzed, a total of 731 variants were
discovered and 39.4% (n  288) were identified as nonsynonymous (Fig. 4A; see also
Data Set S3 in the supplemental material). Of these, 34 unique protein-encoding genes
were mutated in at least 26 of the 33 epidemic genomes and 17% were found to be
involved in inorganic ion transport and metabolism (Fig. 4B; see also Data Set S4).
Epidemic genomes were divided by state and characterized in the same manner to
identify state-specific mutations. California epidemic genomes contained more variants
than Vermont (561 and 413, respectively), with a majority of noncoding mutations
(82%) specific to California genomes and a majority of nonsynonymous mutations
(53%) specific to Vermont epidemic genomes (Fig. 4A; see also Data Sets S5, S6, S7, and
S8). The California isolate H375, the only isolate from the ptxP1 lineage, exhibited the
largest number of isolate-specific variants of all epidemic genomes (n  90) and
accounted for seven additional noncoding variants upon exclusion from the California-
specific variant analysis (Fig. 4A; see also Data Set S3). The genes affected by nonsyn-
TABLE 2 Characteristics of rearrangement boundaries
Characteristic
Value for strain type:
Epidemic Epidemic and vaccine
No. of genomes 31a 33a
No. of rearrangement boundaries 25 44
No. of copies/genome
IS481 (231) 20 39
rRNA (3) 3 3
IS1002 (4) 1 1
IS1002/IS481 1 1
aI488 and I517 excluded from analysis.
TABLE 3 Unique SNPs in virulence-related genesa of B. pertussis epidemic isolates compared to E476 (Tohama I)
Gene Isolate(s) SNP location Region characteristic Amino acid change Protein expressed? (49) Reference(s)
bapC H374 655 A¡G String of 2 G’s 219 Asp¡Gly Unknown This study
bfrD H564 1634 G¡A GC-rich region 545 Ser¡Asn Unknown This study
bipA H563 1070 G¡T GC-rich region 357 Arg¡Leu Unknown This study
brkA I646 640 C¡T GC-rich region 214 Pro¡Ser Unknown This study
bscC H375 1677 G¡A String of 2 A’s NAb Yes This study; 49
bvgR C393 36 C¡T String of 3 T’s NA Unknown This study; 23
bvgS All epidemic isolates, C393 2113 A¡G GC-rich region 705 Lys¡Glu Yes 47, 49, 50, 51, 52
fimD All epidemic isolates, C393 356 T¡C GC-rich region 119 Phe¡Ser Yes 47, 49, 50, 53, 54
ptxB All epidemic isolates 133 G¡A GC-rich region 45 Gly¡Ser Yes 47, 49, 50, 55
ptxC All epidemic isolates
except H375
681 C¡T String of 2 T’s NA Yes 47, 49, 56
aDoes not include previously identified SNPs associating with MLST typing loci.
bNA, not applicable.
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onymous mutations specific to each state were further identified (Table 4). In at least
nine of the 12 California epidemic genomes, 63% (n  5) of the nonsynonymous
mutations were seen in five IS1663 elements (Table 4; see also Data Set S9). Nine of the
18 nonsynonymous mutations specific to Vermont affected proteins involved in various
metabolic pathways (Table 4; see also Data Set S9). Additionally, no variants were found
to be exclusive to prn-deficient isolates outside the prn gene or isolates collected from
fatal cases.
To address the issue of vaccine-driven evolution and to determine if certain genes
are under selective pressure, the frequencies of nonsynonymous variants and variants
within virulence genes across all epidemic genomes were determined. Virulence gene
variants had a rate of 0.22 bp/kb compared to 0.24 bp/kb for total epidemic genome
variants, with no significant difference between the two. However, nonsynonymous
variants had a higher frequency (0.10 bp/kb) than synonymous variants (0.03 bp/kb)
(P value  0.0029).
DISCUSSION
This study illustrates the first effort to evaluate relationships among isolates within and
between statewide pertussis epidemics through comparison of complete genome
sequences. Prior to the availability of single-contig genomes, PFGE has been the only
whole-genome indicator used to fully assess molecular epidemiology and patient
transmission of circulating strains of B. pertussis (34). To date, analyses of gene order
and genome structure heterogeneity have been limited by the resolution of available
















































FIG 3 Maximum likelihood phylogenetic reconstruction from the concatenated alignment of 408
variable sites (SNVs and MNVs). Vaccine strains resequenced in this study are indicated in black,
California isolates are indicated in blue, and Vermont isolates are indicated in red. Yellow circles
denote pertactin-deficient strains, and black circles denote strains recovered from fatal cases. The
scale bar indicates number of substitutions per site and has been corrected for ascertainment bias
based on the nucleotide composition of invariant sites in E476. All epidemic genomes were included
in this analysis.
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assembly that has been confirmed with a second method such as optical mapping.
During the process of complete genome assembly, genome optical maps not only
provided structural confirmation of assemblies but proved to be useful as a possible
genome typing tool with greater detail than that found with PFGE (with approximate
location of restriction cut sites mapped). Depending on future questions, it may be
beneficial to develop a hierarchical approach, in which optical mapping is first used to
compare genome structures as a typing method, followed by genome sequencing if
more detail is required.
Here, we generated high-quality genome assemblies and showed their capacity for
detecting discrete genome structural variations among two geographically and tem-
[C] Energy production and conversion
[E] Amino acid transport and metabolism
[G] Carbohydrate transport and metabolism
[I] Lipid transport and metabolism
[J] Translation, ribosomal structure, and biogenesis
[K] Transcription
[L] Replication, recombination, and repair
[M] Cell wall/membrane/envelope biogenesis
[P] Inorganic ion transport and metabolism
[Q] Secondary metabolite biosynthesis, transport, and catabolism
[T] Signal transduction mechanisms
[V] Defense mechanisms
0 25 50 75 100
H375-specific variants (n=90)
VT-specific variants (n=34)





























FIG 4 Sequence variants within epidemic genomes. (A) Distribution of noncoding (green), synon-
ymous (yellow), and nonsynonymous (blue) variants. (B) Functional classification of predicted protein
sequences with observed nonsynonymous mutation in at least 26 epidemic genomes categorized
according to EggNOG v.4. Variants were statistically significant by Fisher’s exact test.
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porally independent pertussis epidemics at a resolution never seen before. Further-
more, clustering these genomes according to rearrangement patterns revealed corre-
lations with PFGE profiles and associating prn mutations. However, no strong
association was observed between global genome structure and geography, patient
fatality, vaccination status, or time of collection (Fig. 2; Table 1). The genome structures
of two vaccine strains resequenced as part of this study differed greatly from epidemic
isolates, supporting a growing body of evidence that suggests that current circulating
strains of B. pertussis have dramatically changed since the isolation of vaccine refer-
ences (Fig. 2).
Recently, Bart et al. (29) sequenced complete genomes of representative isolates
from two predominate global lineages of ptxP3 and ptxP1 (B1917 and B1920, respec-
TABLE 4 State-specific nonsynonymous variants in California and Vermont epidemic B. pertussis genomesa










Transposase for IS1663 Replication, recombination,
and repair
116940 947 T¡A 316 Leu¡Gln 13
Transposase for IS1663 Replication, recombination,
and repair
527395 805 T¡C 269 Tyr¡His 12
Transposase for IS1663 Replication, recombination,
and repair
1080959 947 T¡A 316 Leu¡Gln 9
Transposase for IS1663 Replication, recombination,
and repair
1090325 947 T¡A 316 Leu¡Gln 10
Transposase for IS1663 Replication, recombination,
and repair
1447860 947 T¡A 316 Leu¡Gln 12
Transposase Replication, recombination,
and repair
3457234 947 A¡T 316 Gln¡Leu 12
Regulator (hypothetical protein) Signal transduction mechanisms 3614341 11 G¡A 4 Gly¡Glu 12
Vermont
Zinc transporter ZupT Inorganic ion transport
and metabolism
198405 194 T¡C 65 Val¡Ala 20
FAD/FMN-containing dehydrogenase Energy production
and conversion
216761 19 T¡C 7 Ser¡Pro 20
RNase E Translation, ribosomal structure,
and biogenesis
489152 2480 C¡T 827 Pro¡Leu 20
Endoribonuclease L-PSP
(RutC family protein)
Function unknown 528567 186 C¡G 62 Asp¡Glu 20





1333208 2519 G¡A 840 Gly¡Asp 20
Aldo-ketoreductase Function unknown 1388597 625 G¡C 209 Ala¡Pro 19
Multidrug efflux pump subunit AcrB Inorganic ion transport
and metabolism
2208591 3221 A¡G 1074 Asn¡Ser 19
Acyltransferase Function unknown 2271460 24 G¡C 8 Gln¡His 17
Hypothetical protein Function unknown 2276856 158 T¡C 53 Val¡Ala 20
Transposase Replication, recombination,
and repair










3011513 1016 C¡T 339 Ala¡Val 20
NADPH dehydrogenase Energy production
and conversion





3538308 166 G¡A 56 Gly¡Arg 11
Putative oligopeptide
transporter
Function unknown 1189451-1189452 1765_GC_1766 589 Gly fs 19
ATP-cobalamin adenosyltransferase Coenzyme transport and
metabolism
3304784-3304785 545_CCGG_546 183 Ala fs 17
Hypothetical protein Function unknown 3490857-3490858 1130_CTA_1131 377 Glu delins Asp* 20
aAbbreviations: fs, frameshift; delins, deletion/insertion; FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; PSP, perchloric acid-soluble protein; *, produces
premature stop codon.
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tively) which exhibited structural architectures similar to those of the U.S. epidemic
isolates reported here with comparable molecular typing profiles (Table 1; Fig. 2). The
finding that B1920 clustered near the only ptxP1 epidemic isolate may indicate a shift
in rearrangement profiles that corresponds to the shift from ptxP1 and ptxP3 lineages.
Additionally, B1917 and B1920 strains were isolated in 2000 in the Netherlands,
temporally and geographically distant from the epidemic isolates sequenced here,
suggesting that rearrangement profiles may be stable over time. Although rearrange-
ments have been identified by others, attempts to measure rearrangement rates in
B. pertussis have been limited by the low resolution of PFGE, and reports of gene order
changes following multiple laboratory passages, which differ from natural infection
cycles, are conflicting (36–40). Therefore, the historical pattern of genome rearrange-
ment remains unclear. Only through methods like optical mapping and complete
genome sequencing, which have been applied to B. pertussis U.S. epidemic isolates
here for the first time, can these questions be addressed.
Although a diverse number of PFGE profiles among isolates are observed in this and
previous studies, the genomic variation underlying this diversity can now be interro-
gated (11). To do so, we identified genes located at predicted rearrangement bound-
aries in all fully assembled genomes in this study. The highly conserved rrn operons and
repetitive mobile elements IS481 and IS1002 were found at predicted rearrangement
breakpoints in both epidemic and vaccine isolate genomes, the majority of which were
composed of IS481 elements (Table 2; see also Fig. S1 in the supplemental material).
Almost all predicted rearrangements were in the form of inversions flanked by inverted
sequence repeats, often “symmetric” around the origin or terminus of replication,
maintaining replichore balance important for genome stability (41, 42). These data
support previous evidence that rearrangements in the B. pertussis genome are medi-
ated by insertion sequence (IS) elements through homologous recombination between
inverted repeats, presumably during replication, a mechanism long thought to main-
tain genome plasticity (22, 35, 36, 41, 43, 44).
Aside from rearrangements, mobile elements have been shown to play a role in the
creation of pseudogenes, genome reduction, and adaptive evolution toward host
specificity (22, 36, 43, 45, 46). Accurate identification of all IS481, IS1002, and IS1663
insertions is necessary to evaluate their contribution to genome evolution, and previ-
ous studies using short-read sequencing have been unsuccessful (24, 47). Our pipeline
provided more robust sequencing data for proper placement of insertion sequences to
construct more accurate assemblies, evident when comparing the corrected number of
IS481 elements discovered in the resequenced vaccine strains E476 and C393 and
assembly structure errors found when comparing the NCBI CS reference genome with
the resequenced C393 (see Data Set S1 in the supplemental material). Alignment of
complete genome sequences provides further evidence that IS481 transposition re-
mains active, consistent with previous reports, but also suggests that this expansion of
repetitive sequence may provide additional opportunities for rearrangement (48). With
the exception of H561, most Vermont and California epidemic genomes contained
more IS481 copies than both Tohama I and E476. Additionally, further acquisition of
insertion sequence copies in currently circulating strains of B. pertussis may indicate
intraspecies host adaptation through gene inactivation that allows B. pertussis to evade
protective immunity elicited by the acellular vaccine and cause disease in a vaccinated
population. This claim is further supported by studies indicating that the majority of
prn-deficient U.S. isolates harbor an IS481 within the prn gene locus (11, 15). However,
the results of this study suggest that the role of mobile elements in B. pertussis genome
evolution may not be limited to reduction, raising questions about the potential fitness
implications of rearrangement, as others have also speculated (40).
In an effort to identify potential correlates of protection not included in the U.S.
acellular vaccine, nonsynonymous mutations were investigated in 40 additional
virulence-related genes and throughout the genomes of all epidemic isolates. Many
virulence-related gene mutations were identified in isolates collected from infants and
children with various effects on amino acid sequence within either a single isolate or all
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epidemic isolates (Tables 1 and 3) (23, 47, 49–56). Although statistically insignificant
due to the small sample size of this study, rates of SNPs in virulence genes seem to
support the idea of genetic drift and are not found to occur more frequently than in
other genes. However, the rate of nonsynonymous variants suggests that genetic
elements might be under selective pressure. The majority of nonsynonymous muta-
tions (53%) were found to affect proteins either identified as transporters or associated
with the transport and metabolism of various cellular molecules (Fig. 4B; see also Data
Set S4 in the supplemental material). This overrepresentation of SNPs in transport
proteins was also seen in a study of SNP density in the global population of pertussis
isolates and may provide insight into the mechanism by which current strains have
adapted to the current global vaccination state (24). Although state-specific mutations
were discovered in IS elements and metabolic proteins in California and Vermont,
respectively, it is difficult to make phenotypic implications based on state specificity,
disease presentation, or demographic due to the highly biased selection of the small
number of isolates chosen for whole-genome sequencing and the lack of a functional
assessment in the study. Transcriptomics, protein expression, and functional assays of
proteins affected by nonsynonymous mutations in these genomes are needed to fully
understand how these mutations affect the ability of B. pertussis to infect and cause
disease, with varying severity, in the host.
It is clear that we do not fully understand the correlates of protection against
B. pertussis. However, this study has expanded our understanding of prn deficiency,
specifically with genomic data visualizing the true nature of the previously predicted
promoter inversion and providing evidence that no conserved single or multiple
mutational events may be compensating for prn deficiency in this collection of isolates,
calling into question the role that pertactin plays in pertussis disease (11, 15). This
analysis in conjunction with proteomics investigation of several of these isolates, which
we are actively pursuing, provides a starting point for determining what proteins are
required for disease in certain host populations while identifying potential candidates
for future vaccine components.
Advances in next-generation sequencing technology, whole-genome mapping, and
bioinformatics improve access to complete genomes, which allow comparative analy-
ses at both the nucleotide and the structural levels. In this study, we compared 31
complete genomes from two recent statewide B. pertussis epidemics with vaccine
strains and observed the first definitive view of genome structural variation through
rearrangement at a nucleotide sequence resolution within this species. These data
challenge the previously held view of population clonality, revealing new levels of
diversity, even within geographically defined epidemics. As more complete genomic,
transcriptomic, and proteomic data are made available for additional strains collected
across broader time periods, it will become possible to discern the stability and rate of
rearrangements, when certain structural profiles emerged, and whether profiles shift
between epidemic and nonepidemic years. Such further analyses are needed to
determine how rearrangement events correlate with SNP phylogenetic relationships
and aid development of a comprehensive typing methodology that incorporates
nucleotide and structural variation to draw meaningful conclusions from associated
clinical metadata. It remains unclear if and how rearrangements play a role in adaption
and virulence. Genomes of isolates collected from asymptomatic carriers are needed as
a baseline, in conjunction with transcriptomic and proteomic analysis, to determine
what insertion elements or rearrangements, if any, are specific to increased disease
severity in some patients. Although this study cannot link rearrangements to virulence
or adaptation, it highlights the need for complete assemblies to fully evaluate the
contribution of pathogen evolution, in addition to waning immunity and incomplete
protection from current vaccines, toward pertussis reemergence.
MATERIALS AND METHODS
Bacterial strains. Isolates submitted to the California Department of Public Health (CDPH) were received
in three manners. First, local health departments passively submitted isolates to CDPH after performing
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primary isolation or after hospital submission. For B. pertussis deaths, CDPH actively reached out to the
local health jurisdiction or hospital to determine if an isolate was available and requested submission to
CDPH. Additionally, in 2010 local public health laboratories were sent a request for submission to CDPH
of any B. pertussis isolate that had not been previously submitted. The 13 California isolates sequenced
in this study (Table 1) were chosen as part of a collaborative project between CDPH and the CDC focused
on determining the phylogenetic relationship of B. pertussis isolates from California infants less than
3 months old where B. pertussis infection led to either fatal or nonfatal pertussis disease (49). From
November 2011 to December 2012, 4,100 nasopharyngeal specimens were received at the Vermont
Department of Health Laboratory (VDHL) from pediatric practices and hospitals and tested by culture
and, if ordered by the physician, by PCR. During the outbreak, 72% of all PCR-positive specimens were
confirmed by culture, of which the VDHL submitted 432 isolates to the CDC in 2013 for molecular
characterization. In general, prn genotype and PFGE profiles were taken into account to select the most
diverse pool of 20 Vermont isolates used for whole-genome sequencing. The CS strain (C393) and
Tohama I isolate (E476) were also resequenced in this study (Table 1).
Genomic DNA preparation. Isolates were cultured on Regan-Lowe agar without cephalexin for 72 h
at 37°C. Genomic DNA isolation and purification were conducted according to the Qiagen Gentra
Puregene yeast/bacterial kit standard protocol with slight modification (Qiagen, Valencia, CA). Briefly, two
aliquots of approximately 1  109 bacterial cells were harvested and resuspended in 500 l of 0.85%
sterile saline and then pelleted by centrifugation for 1 min at 16,000  g. Following the protocol to
completion, 100 l of DNA hydration solution was added to dissolve the genomic DNA. Aliquots were
quantified and qualified using a NanoDrop 2000 (Thermo Fisher Scientific Inc., Wilmington, DE) spec-
trophotometer.
Genome sequencing and assembly. Whole-genome shotgun sequencing of each isolate was
performed using a combination of the PacBio RSII (Pacific Biosciences, Menlo Park, CA) and Illumina
MiSeq (Illumina, San Diego, CA) platforms. Genomic DNA libraries were prepared for PacBio sequencing
runs using the SMRTbell template prep kit 1.0 and polymerase binding kit P4, while MiSeq libraries were
prepared using the NEB Ultra Library prep kit (New England BioLabs, Ipswich, MA). PacBio sequencing
reads were filtered with the following cutoffs: 500-bp minimum subread length, 0.80 minimum poly-
merase read quality, and 100-bp minimum polymerase read length. De novo genome assembly of passed
reads was performed first using the Hierarchical Genome Assembly Process (HGAP, v3; Pacific Biosci-
ences) with a 6-kb minimum seed read length, 15 target coverage, 0.06 overlap error rate, and 40-bp
minimum overlap length (57). These initial assemblies were further improved by unambiguously mapped
PacBio reads with a minimum length of 50 bp and quality score of 75 using BLASR (v1) with a maximum
divergence of 30% and minimum anchor of 12 bp (28). The resulting consensus sequences were
determined with Quiver (v1), manually checked for circularity, and then reordered to match the start of
the CS reference sequence (NC_017223).
Assemblies were confirmed by comparison to restriction digest optical maps (as described below)
and further “polished” by mapping Illumina MiSeq PE-150 reads using CLC Genomics Workbench (v7.5;
CLC bio, Boston, MA). Raw reads were first trimmed at both ends to remove bases with quality scores less
than 0.01 and ambiguous nucleotides and then filtered to remove reads less than 45 bp. The resulting
trimmed reads were mapped against the HGAP assembly with the following parameters: mismatch cost
of 2, insertion/deletion cost of 3, length fraction of 0.95, similarity fraction of 0.95, and local alignment
end gap calculation. Potential errors were identified using the Basic Variant Detection module with the
following parameters: maximum coverage of 1,000, minimum coverage of 10, minimum read count
of 5, minimum variant frequency of 51%, neighborhood radius of 5 bp, minimum central quality score
of 25, and minimum average neighborhood quality score of 20. Detect errors were then corrected either
manually or with a custom Perl script. Assembly statistics are detailed in Data Set S1 in the supplemental
material. Final assemblies were annotated using the NCBI automated Prokaryotic Genome Annotation
Pipeline (PGAP).
Optical mapping. Optical maps for each isolate were prepared from cells of single 1-mm colony
equivalents following growth on Regan-Lowe agar without cephalexin using the Argus system (OpGen,
Gaithersburg, MD) according to special company protocols. Briefly, high-molecular-mass bacterial DNA
(205-kbp average size) was isolated with minimal shearing and applied to a chemically modified glass
surface with fabricated microfluidic channels. The stretched DNA on the channels was digested in situ
with KpnI in a partial digestion mode and stained with a JoeJoe fluorescent dye on an automatic
MapCard processor. To confirm revealed unusual insertions and duplications, restriction enzyme BamHI
was used. The digested DNA molecules were imaged using an Argus fluorescence microscope and
Path-Finder automated image-acquisition and tiling optical map assembly software (OpGen). The
resulting single-molecule restriction maps were assembled into consensus whole-genome maps with
Gentig software (OpGen) that recurrently aligned overlapping DNA molecules with similar fragments to
calculate a concluding map. Final whole-genome maps in this study are composites from at least 32
single fragmented molecules at every point and typically represent an average depth of 50 to 300
molecules. Restriction map alignments between different strains were generated using MapSolver
software (v.2.1.1; OpGen, Gaithersburg, MD). Pairwise alignments were performed between all maps
using an alignment score of 3. Optical maps for each of the 33 epidemic isolate and vaccine strain
single-contig assemblies were compared to the in silico restriction map of the vaccine isolate Tohama I
(NC_002929.2) using MapSolver as an independent validation. Optical maps were also compared to in
silico digests of HGAP assemblies to confirm genome structure, and when necessary, de novo assemblies
were repeated.
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Whole-genome alignment. Whole-genome assemblies of epidemic isolates were aligned using
progressiveMauve (58) along with C393, E476, and four publicly available complete genomes: CS
(NC_017223), Tohama I (NC_002929), B1917 (CP009751), and B1920 (CP009752). Genomes were clustered
based on changes in order and orientation of homologous sequence blocks using the MLGO pipeline
(59). Multicontig assemblies for I488 and I517 were excluded from whole-genome alignment and
rearrangement analyses.
Virulence gene and variant analysis. Genome assemblies for all 33 epidemic isolates were
compared to E476 (Tohama I) using CLC Genomics Workbench. Coding regions of 44 known virulence
genes were found using BLASTn and aligned against E476 using MEGA6 (60) to detect SNPs and predict
resulting amino acid changes. All SNPs were confirmed by manual inspection of Illumina read align-
ments. Additionally, we have proposed the nomenclature of two genes, fimW (fim2) and fimH (fim3), to
better conform to bacterial nomenclature standards and avoid confusion in allele typing.
Whole-genome variant analysis was performed by mapping from Illumina reads of each isolate to the
E476 genome. The mapping parameters were the same as described for genome “polishing” above with
a few exceptions. These exceptions include a length fraction of 0.90 and a similarity fraction of 0.90.
Variants were determined using the Basic Variant Detection tool in CLC Genomics Workbench. A
phylogenetic tree was constructed from single nucleotide variants (SNVs; n  758) and multiple
nucleotide variants (MNVs) (n  123) after removal of variants in proximity to IS481 and IS1002 insertions.
The resulting 408-bp concatenated alignment was used to calculate a maximum likelihood phylogenetic
reconstruction with ascertainment bias correction using RAxML v8 (61). Proteins containing nonsynony-
mous mutations were predicted based on the E476 genome annotation information and then were
further classified into functional categories using HMMER v3.1b2 (http://hmmer.org/) (62) to search a
betaproteobacterium-specific subset of EggNOG ver. 4.1 (63).
Nucleotide sequence accession numbers. The whole-genome shotgun sequences have been
deposited at DDBJ/EMBL/GenBank under the accession numbers CP010249 to CP010266, CP010347,
CP010838 to CP010847, CP010961 to CP010964, JWLA00000000, and JWLB00000000. The versions
described in this paper are the first versions. The project description and related metadata are accessible
through BioProject number PRJNA266616.
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